For healthcare professionals. This information does not replace clinical judgement in the individual case; the current summary of product characteristics and the guidelines cited are authoritative.
Medically reviewed: Dr. med. univ. Daniel Pehböck, DESA, 01.11.2026
Enoxaparin (Low-molecular-weight heparin (predominantly anti-Xa activity)) – indications: STEMI – primary PCI (alternative to UFH), STEMI – adjunct to fibrinolysis, Pulmonary embolism / deep vein thrombosis – treatment (haemodynamically stable). Weight-based dosing in mg and ml in the app, with sources.
Indications
- STEMI – primary PCI (alternative to UFH)
- STEMI – adjunct to fibrinolysis
- Pulmonary embolism / deep vein thrombosis – treatment (haemodynamically stable)
Complete in the app
Weight-based doses in mg and ml, preparations, contraindications and notes – in the app, also offline.
Used in
Sources and guidelines
- Byrne RA, Rossello X, Coughlan JJ et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44:3720–3826.
- Summaries of product characteristics of authorised products – product and section for each dose in the app.